Related Experiment Video

Updated: Dec 14, 2025

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
10:24

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases

Published on: June 30, 2019

10.4K

Structure-activity relationships of Wee1 inhibitors: A review

Xingkai Du1, Jian Li2, Xiaojiao Luo1

  • 1State Key Laboratory of Biotherapy & Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center of Biotherapy, Chengdu, 610041, China.

European Journal of Medicinal Chemistry
|July 21, 2020
PubMed

Insights

Wee1 kinase inhibitors show promise for cancer therapy, especially in p53-mutated cancers. This review systematically summarizes their structure-activity relationships, aiding future drug design.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • Wee1 kinase regulates cell cycle progression, crucial for G2/M checkpoint control.
  • Wee1 inhibition induces mitotic catastrophe in cancer cells, particularly those with p53 mutations.
  • Wee1 kinase is a significant target for cancer therapy development.

Purpose of the Study:

  • To systematically review the structure-activity relationships (SARs) of Wee1 inhibitors.
  • To consolidate information on structural types, binding modes, and SARs of reported Wee1 inhibitors.
  • To provide insights for the rational design and development of novel Wee1 inhibitors.

Main Methods:

  • Literature review of scientific journals reporting on Wee1 inhibitors.
  • Systematic summary of structural diversity and SAR data.
  • Analysis of binding modes and their correlation with inhibitory activity.

Main Results:

  • A comprehensive overview of various Wee1 inhibitor scaffolds and their SARs.
  • Detailed analysis of how structural modifications impact Wee1 inhibitory potency.
  • Identification of key structural features responsible for Wee1 binding and inhibition.

Conclusions:

  • Understanding SARs is critical for optimizing Wee1 inhibitor efficacy.
  • This review facilitates the rational design of next-generation Wee1 inhibitors.
  • Wee1 inhibitors represent a promising therapeutic strategy for specific cancer types.
Keywords:
Cancer therapyCell cycle checkpointStructure-activity relationshipsWee1 inhibitors

More Related Videos

Author Spotlight: Establishing CENP-E Knockout HeLa Cells – A Novel Approach to Study Kinesin-7 CENP-E Biology and its Inhibitors11:49

Author Spotlight: Establishing CENP-E Knockout HeLa Cells – A Novel Approach to Study Kinesin-7 CENP-E Biology and its Inhibitors

Published on: June 23, 2023

1.1K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.4K

Related Concept Videos

Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
89.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.5K
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
19.2K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.8K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
8.4K